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The dysregulation of metabolism in malignant cells has been
established for over 80 years. It has been known as the “Warburg
effect”, from the scientist who ﬁrst observed an increase of glycolysis in
cancer cells, even in the presence of oxygen, without an accompanying
increase in respiratory chain production of energy [1,2]. So far the
underlying reasons for aerobic glycolysis are unknown, but may be
related to the different behavior of malignant cells, so that survival,
growth and division are favored over functions. The switch from
respiration to glycolysis has usually been considered a consequence
rather than a cause of cancer. However, the discovery in the last
ten years that inherited alterations in mitochondrial enzymes cause
hereditary tumors has changed this viewpoint. These alterations
comprise germline mutations in the genes encoding succinate dehy-
drogenase (SDH) enzyme subunits [3–6], succinate dehydrogenase
complex assembly factors 2 (SDHAF2) [7] and fumarate hydratase
(FH) [8]. Moreover, recently, somatic mutations in IDH1 and IDH2
genes, encoding isocitrate dehydrogenases 1 and 2 respectively, have
been identiﬁed in a high proportion of glioblastomas [9,10].
The succinate dehydrogenase enzyme (also known as succinate-
ubiquinone oxydoreductase) is a highly conserved heterotetrameric
protein, with SDHA and SDHB as catalytic subunits, which protude
into the mitochondrial matrix and are anchored to the inner
membrane by SDHC and SDHD. These latter subunits provide also
the binding site for the ubiquinone (Fig. 1). All the subunits are
encoded by nuclear genes and then imported into the mitochondriawhere they are modiﬁed, folded and assembled. Unlike most of the
Krebs cycle enzymes, SDH has no cytosolic counterpart. This enzyme
comprises mitochondrial complex II, which is involved in the Krebs
cycle and in electron transport chain (ETC) [11]. Complex II couples
the oxidation of succinate to fumarate in the Krebs cycle with the
electron transfer to the terminal acceptor ubiquinone in the ETC.
Germline mutations in SDHD, -B and -C, were observed in patients
with hereditary paragangliomas and phaeochromocytomas [3–5] and
(rare) somatic mutations were detected in the corresponding non-
syndromic lesions [12–14]. Recently, mutations in genes encoding
the subunit A of SDH (SDHA) and the SDH assembly factor 2 (SDHAF2),
were found to be associated with hereditary paraganglioma and
phaechromocytoma syndrome (HPGL/PCC) [6,7]. The genetic lesions
in the SDH genes predisposing to the HPGL/PCC syndrome are
germline heterozygous mutations, which cause inactivation of the
protein function. The neoplastic transformation occurs when there is
the loss of the remainingwild type allele in the somatic cells, i.e. loss of
heterozygosity, leading to the complete loss of the enzyme function.
Thus, SDH act as a classical tumor suppressor genes [12,15,16]. This
article will review the latest current research in this ﬁeld.
2. Hereditary paraganglioma-phaeochromocytoma
syndrome (HPGL/PCC)
Paragangliomas (PGLs) are rare tumors, deriving from paraganglia,
neuroendrocrine tissues symmetrically distributed along the para-
vertebral axis from the base of the skull and the neck to the pelvis.
The two major paraganglionic organs in the adult are represented
by the carotid body and the adrenal medulla. The carotid body
detects oxygen and carbon dioxide partial pressure changes in the
arterial blood, but is also sensitive to pH and temperature. The adrenal
Fig. 1. Succinate dehydrogenase complex (SDH) in the electron transport chain and Krebs cycle. SDH is the only membrane-bound enzyme of the Krebs cycle and is also a functional
member (complex II) of the electron transport chain (ETC). SDH is a complex of four different polypeptides (SDHA, SDHB, SDHC and SDHD) together with several prosthetic groups
that include FAD, non haem iron ubiquinone and haemb.
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preganglionic neurons.
Paragangliomas associated with the parasympathetic nervous
system arisemainly in the head and neck region (HNPGLs), particularly
in the carotid bodies (carotid body tumor), along the vagus nerve, in
the jugular foramen and in the middle ear space, and generally do
not hypersecrete catecholamines or other hormones. Paragangliomas
associated with the sympathetic nervous system arise in the adrenal
or extra-adrenal locations. Those arising from chromafﬁn cells of
the adrenal medulla are deﬁned as phaeochromocytomas (PCCs) [17],
while paragangliomas deriving from extra-adrenal sympathetic tissue
conﬁned to the abdomen, thorax and pelvis are referred as extra-
adrenal paragangliomas (extra-adrenal PGLs). Phaeochromocytomas
(also known as adrenal chromafﬁn tumors) and extra-adrenal para-
gangliomas typically hypersecrete catecholamines such as epinephrine
(adrenaline), noraepinephrine (noradrenaline) or dopamine.
HNPGLs are slow growing tumors, generally benign with an
incidence of 1:30,000–100,000 in the general population [18]. Despite
their benign nature, HNPGLs can cause untoward consequences due
to compression of vital organs by the tumor mass. PCCs and extra-
adrenal PGLs give rise to symptoms associated with catecholaminehypersecretion, such as uncontrolled hypertension. Since no accepted
pathological or immunohistochemical marker distinguishes malig-
nant from benign paraganglial tumors, malignant PGLs are deﬁned
by the presence of metastatic lesions at sites where neuroendocrine
tissue is normally absent, e.g. lymph nodes, bone, lung, liver [19]. Thus,
patients who have initially been assumed to have non malignant PGL,
may only later present with unequivocal malignant disease. Extra-
adrenal PGLs have a high risk of malignant progression. Malignancy
is much less likely in adrenal PCCs and HNPGLs, but occurs. Thus
depending on the localization, malignancy has been reported in 2%
to 19% [20,21].
Patients with HPGL/PCC syndrome can present with head and neck
paragangliomas only, adrenal and/or extra-adrenal tumors only, or a
combination of the two types of tumors [22,23].
Paragangliomas occur either sporadically or as a part of hereditary
syndrome. Patients with inherited predisposition often develop
multiple, bilateral and early onset paragangliomas, as a result of
germline mutations in the predisposing genes.
Hereditary susceptibility to familial form of head and neck PGLs
was ﬁrst recognized in 1933 by Chase [24]. However, it was about a
decade ago, when the ﬁrst predisposing gene to HPGL/PCC syndrome
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associated with a susceptibility to develop adrenal phaeochromocy-
tomas, such as multiple endocrine neoplasia type 2 (MEN2), von
Hippel Lindau disease and neuroﬁbromatosis type I, caused respec-
tively by germline mutations in RET, VHL and NF1 genes, the study
of inherited predisposition to head and neck paragangliomas led
to the discovery of the novel paraganglioma–phaechromocytoma
syndrome. This syndrome was found to be caused by germline
mutations in SDHD, SDHB and SDHC genes. Initially linkage analysis
identiﬁed on chromosomes 11 and 1 three PGL susceptibility loci,
which were labeled respectively ‘paraganglioma locus 1’ (PGL1) on
11q23 [25–28], PGL2 on 11q13.1 [29,30], PGL3 on 1q21 [31,32].
Subsequently, gene mapping studies led to the discovery of SDHD as
the gene responsible for PGL1 in familial HNPGLs [3]. Following
studies then revealed that mutations in the SDHC (PGL3) and SDHB
(PGL4, 1p36.1–p35) genes can also cause familial PGLs and PCCs [4,5].
Recently, the susceptibility gene for PGL2 was identiﬁed as SDHAF2
gene (succinate dehydrogenase complex assembly factor 2) [7]. In
addition, a germline mutation in the SDHA gene was identiﬁed in a
patient suffering of catecholamine-secreting abdominal PGL, suggesting
that SDHA is an additional paraganglioma/phaeochromocytoma
susceptibility gene [6].
An updated database of all reported SDH allelic variants, which
cause familial PGL syndromes is available online: http://chromium.
liacs.nl/lovd_sdh/ [33]. This database is based on the Leiden Variation
Database (LOVD) system.
Susceptibility to HPGL/PCC is transmitted in an autosomal
dominant manner with age-dependent and incomplete penetrance.
Although the incidence of PGLs in the general population is low,
it is noteworthy that 38% to 60% of individuals with underlying
SDHD, -B, -C mutations will develop PGLs by 35 years old [34]. SDHD
mutations conferred 50% penetrance by 40 years of age and 80%
by 60 years of age. SDHB mutation carriers were shown to have a
penetrance of 40% for paraganglial tumors by 40 years age, which
increased to 70%by the age of 60 [35]. The prevalence of underlying SDH
mutations is 10% to 30% among patients with apparently sporadic PGLs
and 10% to 70% among patients with familial PGLs [22,23,34,36–45].
In addition, it has been reported that 8–12.5% of non-syndromic, non-
familial extra-adrenal PGLs and PCCs carry occult germline mutations
in SDHB or SDHD genes [42]. Interestingly PGLs, which develop in
susceptible families, are more aggressive and with an increased risk
of metastasis and mortality [23,34,43,44].
2.1. SDHD (PGL1)
The hereditary syndrome PGL1 (OMIM ID: 168000) is caused by
mutations in the SDHD gene (RefSeq: NM_003002.2; 11q23.1; SDHD
Leiden Open Variation Database http://chromium.liacs.nl/LOVD2/
SDH/home.php?select_db=SDHD). This gene encodes the integral
membrane-anchoring protein cybS, which together with cybL encoded
by SDHC, comprise respectively the small and the large subunits of
the heme-protein cytochrome b in the mitochondrial complex II.
SDHD mutations are typically associated with multifocal HNPGLs
and less frequently with adrenal PCCs and extra-adrenal PGLs, which
are usually benign [23,34,46]. Rare cases of metastatic HNPGLs have
been described within SDHD mutation carriers and their estimated
prevalence is 0–10% [23,34,35,46–52].
Recurrent mutations with a founder effect have been identiﬁed
in Dutch (p.Asp92Tyr, p.Leu95Pro, p.Leu139Pro) [36,53], American (p.
Pro81Leu) [22], Italian (p.Gln109X) [54], Chinese (p.Met1Ile) [36,55]
and Spanish (p.Trp43X) [56] families. Furthermore a large SDHD
founder deletion (4944-base pair) between Alu elementswas recently
indentiﬁed in two Austrian families with hereditary head and neck
PGLs [57].
Although PCCs and extra-adrenal PGLs are relatively rare in
patients with SDHD germline mutations, recently Ricketts and co-authors described that SDHDmutations predicted to result in an absent
or unstable SDHD protein were associated with an increased risk
of PCCs and extra-adrenal PGLs, compared to missense mutations
or in-frame deletions, which were not predicted to impair protein
stability [35].
SDHD-related disease has been characterized by a parent-of-origin
effect, as it is transmitted only when the mutated allele is inherited
from the father [22,23,46]. This pattern of inheritance suggested
maternal genomic imprinting of this gene. In support of this idea
Badenhop and colleagues showed expression of only the mutant
paternal SDHD allele in tumor samples [58]. However, subsequent
studies did not support this hypothesis, but demonstrated bi-allelic
expression of SDHD in different normal tissues and in neural crest-
derived tumors, with no promoter hypermethylation in normal
adrenal tissues or phaeochromocytomas [3,49,59–61]. Moreover,
further studies demonstrated that SDHD does not belong to an
imprinted DNA region [62]. Since allelic loss in SDHD-associated
paragangliomas always involves the entire wild type maternal allele
[3,63], it was proposed that the observed pattern of inheritance
resulted from the effects of a gene cluster on the same chromosome as
SDHD, but at a distant site (11p15). Thus a growth advantage could be
gained when the wild type maternal SDHD allele on 11q23 and a
maternally active, but paternally imprinted tumor suppressor gene
(TSG) mapped on 11p15, is lost simultaneously [63]. Interestingly,
loss of 11p was shown in 33–50% of HNPGLs, in 27% of abdominal
PGLs, in 17–48% of sporadic PCCs and in 40% and 86% of PCCs from
MEN2 and von Hippel-Lindau (VHL) patients, respectively [18,64–67].
Further evidence supporting the idea that a locus located on the same
chromosome as SDHD could be involved in the parent-of-origin effect
of this gene, came from the study of Pigny and colleagues. In this
work the authors described for the ﬁrst time the occurrence of PGL
in a case of maternal transmission of a SDHD-mutated allele. In this
report genetic analysis of a patient suffering of a jugulo-tympanic PGL,
showed a gain of imprinting in the region upstream of the maternally
expressed H19 gene. Interestingly, this gene was known to be
paternally imprinted. The patient, who inherited the mutated allele
from his mother, carried hypermethylation of two CpGs within the
differentially methylated region 1 (DMR1) upstream of H19 [68].
To date this is the only reported case of maternal transmission of
a SDHD-linked PGL. Since the patient has not been operated no
material was available for histological and molecular studies of the
tumormass [69], which would add further and important information
of this case.
To test the hypothesis that a maternally expressed imprinted locus
on chromosome 11, could modulate SDHD tumorigenesis, Bayley and
co-authors generated a conventional Sdhd knockout mouse model,
which was crossed with a mouse knockout of a candidate modiﬁer
gene h19, in order to generate a double knockout. Thus to evaluate the
possibility that the loss of these genes together would lead to tumor
development, mice were observed for their entire lifespan. However,
both Sdhd and Sdhd/H19 knockout mice, showed no signs of
paraganglioma or phaeochromocytoma development at any age [70].
2.2. SDHAF2 (PGL2)
The SDHAF2 gene (RefSeq: NM_017841.2; 11q12.2; SDHAF2 Leiden
Open Variation Database http://chromium.liacs.nl/LOVD2/SDH/home.
php?select_db=SDHAF2), also known as SDH5, was recently identi-
ﬁed as the susceptibility gene for the PGL2 syndrome (OMIM ID:
601650). This gene encodes a highly conserved protein, necessary for
the incorporation of FAD cofactor in the subunit A of the succinate
dehydrogenase complex. Correct ﬂavination of the SDHA subunit is
essential for the SDH enzyme activity [7].
To date SDHAF2 mutations have been associated to benign, often
multifocal head and neck paragangliomas, with young age of onset
[7,71,72].
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resulted in decreased stability and impaired functionality of the entire
SDH enzyme complex [7]. A germline loss-of-function mutation in
a conserved region of SDHAF2 (c.232 GNA in exon 2, p.Gly78Arg)
was identiﬁed in a Dutch PGL2 family, affected by head and neck
paragangliomas. This mutation resulted in a decrease in ﬂavination of
SDHA subunits in the tumors of the affected patients. Expression
of the mutant SDHAF2 in vitro demonstrated that the p.Gly78Arg
mutation destabilized SDHAF2 protein and impaired its interaction
with SDHA, resulting in a complete loss of SDH enzyme activity.
Interestingly individual who inherited the mutation from the mother
did not develop the disease, suggesting a SDHD-like parent-of-origin
speciﬁc inheritance pattern for PGL2 syndrome [7].
Subsequently,mutation analysis in Spanish kindred affected by early
onset head and neck paragangliomas, who tested negative for both
mutationsanddeletionsof succinatedehydrogenasegenes, revealed the
identiﬁcation of a second family carrying the p.Gly78Arg mutation in
SDHAF2. This mutation showed a high penetrant phenotype, inherited
via the male line, as described in the Dutch PGL2 family. Haplotype
analysis of the SpanishandDutch patients seemed to exclude a common
genetic origin between the two families, suggesting that p.Gly78Arg
mutation has no founder role but is a recurrent variant, which affects an
important residue for the function of SDHAF2 protein [71].
However, two different studies did not identify any germline
or somatic mutations of SDHAF2 in a large patients' cohorts with
apparently sporadic paragangliomas and phaeochromocytomas,
which have no mutations in the SDHD, SDHC or SDHB genes [71,73].
Neither were gross germline deletions, which might account for the
tumors cases tested negative for SDHAF2 pointmutations, noted in the
subset of patients analyzed [71]. The absence of additional p.Gly78Arg
mutations carriers and of other mutations at the SDHAF2 gene in the
patients' series examined implies that SDHAF2 mutations are rare
in head and neck paragangliomas. Moreover no extra-adrenal PGLs
and PCCs have been linked to mutations in this gene so far, suggesting
that SDHAF2 mutations may not be relevant for the development of
these types of tumors.
SDHAF2 mutation analysis should be suggested in young patients
with head and neck paraganglioma,who tested negative formutations
in SDHD, SDHC or SDHB genes.
2.3. SDHC (PGL3)
The PGL3 syndrome (OMIM ID: 605373) is caused by mutations in
the SDHC gene (RefSeq: NM_003001.3; 1q23.3; SDHC Leiden Open
Variation Database http://chromium.liacs.nl/LOVD2/SDH/home.php?
select_db=SDHC). SDHC constitutes the large subunit (cybL) of
cytochrome b in the mitochondrial complex II.
SDHC mutations were originally believed to be associated only
with HNPGLs, but recently rare cases of adrenal PCCs and extra-
adrenal PGLs were reported [34,74–77].
Germline SDHC mutations appear to be less frequent than SDHB
and SDHDmutations and a limited number of SDHCmutation carriers
have been identiﬁed worldwide [4,34,39,40,44,45,56,74,75,78–80].
In general, the clinical features of SDHC-associated cases are similar
to those found in patients with sporadic HNPGLs. Mutation carriers
typically present with solitary head and neck tumors with incomplete
penetrance and a very low tendency to malignant transformation
[39]. Only a single case of malignant catecholamine-producing carotid
body tumor has been reported in a patient with IVS5+1 GNT SDHC
mutation [79].
An Alu-mediated genomic deletion of 8.4 kb involving exon 6 has
been detected in the SDHC gene. The common haplotype found in the
family and in an unrelated sporadic case, in which the large Alu-
mediated SDHC deletion was identiﬁed, supported a common
ancestral origin for these cases. Moreover, it has been reported that
this large deletion caused PLG3 following both maternal and paternaltransmission, suggesting that SDHC is not characterized by parent-of-
origin effect [80].
Since SDHC-associated mutations are so rare, molecular genetic
testing of SDHC is done only after the screening of SDHD and SDHB.
2.4. SDHB (PGL4)
The PGL4 syndrome (OMIM ID: 115310) is due to mutations in
the SDHB gene (RefSeq: NM_003000.2; 1p36.13; SDHB Leiden Open
Variation Database http://chromium.liacs.nl/LOVD2/SDH/home.php?
select_db=SDHB), which encodes an iron-sulfur protein that together
with SDHA constitutes the catalytic domain of SDH.
SDHB mutations mainly predispose to extra-adrenal PGLs with
high malignant potential and to a lesser extent to adrenal PCCs and
head and neck PGLs [23,46,81–83].
In contrast to the predominantly benign nature of SDHC- and SDHD-
associated tumors, SDHB-related extra-adrenal PGLs can develop into
highly aggressive tumors, which are associated with poor prognosis
and can occur at very young age [16,34,48,83–85]. In fact, although the
mean age of tumor presentation in SDHBmutations carriers is ~30 years
[23,83], there are cases in which the index cases were diagnosed before
10 years of age [35,46,86,87]. This suggests that tumor screening of
asymptomatic SDHB carriers should start as early as 10 years of age.
A high frequency of SDHB germline mutations, identiﬁed in
malignant extra-adrenal PGLs, were reported in different cohorts of
patients examined: 83% [84] 34.3% [23], 71.4% [48], 30% [82], 37.5% [46],
28% at initial presentation, then 97% of patients developed metastasis
2.7±4.1 years after diagnosis [83], 31% [88], 37.5% [34] 20.8% [77]. In
addition tomalignantPGLs, SDHBmutationshavebeen suggestedalso to
be associated with malignant tumors of the extra-paraganglial system,
i.e. renal cell carcinoma [23,35,88–90] and thyroid carcinoma [23,35,91].
Although to date a clear genotype-phenotype correlation for SDHB
mutations does not exist, Ricketts and co-authors recently detected
an association between SDHB missense mutations and an increased
risk of HNPGL, compared to truncating mutations [35].
In the last few years, an increasing number of reports have shown
that gross deletions in the SDHB gene might account for a considerable
number of both familial and apparently sporadic PGL cases, whichwere
previously tested negative for point mutations [34,45,76,85,87,92–98].
Although the clinical manifestations of cases associated with large
deletions in SDHB are not well known due to the small number of cases
described, it seems that they have similar phenotypes and penetrance to
patientswith pointmutations. The large SDHBdeletion-associated cases
described so far presented with adrenal PCCs or extra-adrenal PGLs,
which were frequently malignant and also with HNPGLs. Some cases of
either extra-adrenal or head and neck PGLs due to large SDHB deletions
were also associated to tumors of the extra-paraganglial system
[87,94,97]. SDHB large deletion testing should be considered in patients
with familial PGLs, who lack evidence of point mutations.
Large germline founder deletions in SDHBwere characterized at the
sequence level in multiple unrelated subjects from Netherlands
(7905 bp deletion in the exon 3, c.201-4429_287-933del, p.
C68HfsX21) [96], and Spain (16 kb deletion involving the exon 1, c.1-
10413_73-3866del) [94]. A second example of a SDHB gene deletion
with a founder effect in the Spanish population was reported recently
(c.166_170delCCTCA, p.P56delYfsX5) [56]. In addition, the SDHB splice
site mutation IVS1+1 GNT was found in 4 apparently unrelated
Scottish ancestry families, indicating a possible founder effect [46].
In contrast with SDHD, no parent-of-origin effect was described in
SDHB positive families as both paternal and maternal inheritance has
been observed [99].
2.5. SDHA
The SDHA gene (RefSeq: NM_004168.2; 5p15.33; SDHA Leiden
Open Variation Database http://chromium.liacs.nl/LOVD2/SDH/home.
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succinate dehydrogenase enzyme. This subunit contains a covalently-
attached ﬂavin adenine dinucleotide (FAD) prosthetic group and
binds enzyme substrates (succinate and fumarate) and physiological
regulators (oxaloacetate and ATP).
Germline mutations in SDHA, which result in loss or reduced
enzymatic activity, have been shown to cause neurodegenerative
diseases such as an early-onset encephalopathy, known as Leigh
syndrome [100–103] and a late-onset optic atrophy, ataxia and
myopathy [104]. A single case of a pathogenic SDHA mutation
(c.1664 GNA, p.Gly555Glu) not associated to Leigh syndrome has
been described in a patient with a lethal infantile presentation, which
leaded to death due to respiratory infection and acute hypoglycemia,
before any sign of the syndrome could develop [105]. Recently,
the same SDHA missense mutation, which was reported to cause
a multisystemic failure leading to neonatal death [105] and a
relatively mild Leigh syndrome [103], was also described in a familial
neonatal isolated cardiomyopathy [106]. Interestingly, although
SDHA constitutes the mitochondrial complex II enzyme together
with the other SDH subunits, no experimental evidence have linked
mutations in the SDHB, -C, -D genes to metabolic neurodegenerative
disorders or cardiomyopathies. Recently, however homozygous
germline mutations in the SDHAF1 gene (succinate dehydrogenase
complex assembly factor 1), were observed in patients with SDH-
defective infantile leukoencephalopathy syndrome [107].
Mutations in all the other SDH genes and in SDHAF2 have been
associated with paraganglioma-phaeochromocytoma syndrome. It
has been proposed that the absence of SDHA mutations in tumors
related to HPGL/PCC syndrome might be due to the identiﬁcation of
two distinct genetic loci for SDHA, which encoded two different
isoforms with similar enzymatic activity [108,109]. Thus, in order to
obtain inactivation of SDHA in the PGL tumors tetrallelic mutations
should be required [108,110], making SDHA an improbable tumor
suppressor gene. However, this theory was not supported by further
studies, which demonstrated that SDHA is encoded by a highly
polymorphic single gene [111].
Recently, however, Burnichon and co-authors identiﬁed a heterozy-
gous germline SDHAmutation (c.1765 CNT, p.Arg589Trp), in a woman
suffering from catecholamine-secreting abdominal paraganglioma.
In vivo and in vitro functional studies demonstrated that the p.
Arg589Trp mutation abolished SDH enzymatic activity in the yeast
model and in the patient's tumor tissue. The authors showed that
the mutation was associated with somatic loss of heterozygosity at
the SDHA locus within the tumors, demonstrating that SDHA, like the
others SDH genes, can act as a tumor suppressor gene [6].
This ﬁnding suggests that also SDHA should be considered
as a susceptibility gene for paraganglioma/phaeochromocytoma
syndrome. However, SDHA-related tumors are rare, as demonstrated
by the relatively low frequency of LOH at the chromosomal region
containing the SDHA locus (5p15) in the PGL tumors, compared with
the 1p36 (SDHB) and 11q23 (SDHD) loci that often undergo losses in
tumor tissues [6].
Thus, SDHA genetic screening should perhaps be added to
paraganglioma or phaeochromocytoma affected patients, who show
loss of SDH enzymatic activity but tested negative for SDH genes
mutations or if loss of 5p15 chromosome is found in the tumor.
3. SDH mutations in other tumor types
In addition to head and neck PGLs, extra-adrenal PGLs and PCCs, a
number of other neuroendocrine or non-neuroendocrine neoplasms
have been associated with mutations in SDH genes. These include
gastrointestinal stromal tumors (GISTs), renal tumors, thyroid tumors,
testicular seminoma and neuroblastomas.
The best known association between SDH germline mutations
and other tumors is represented by the Carney–Stratakis syndrome(or dyad). The patients affected by this syndrome develop GISTs and
PGLs, which have been associated with germline point mutations or
large deletions of the genes encoding the subunits B, C or D of SDH.
The tumor suppressor function of SDH in the GIST neoplasms, was
demonstrated by the allelic losses around the SDHB and SDHC
chromosomal loci in the samples of patients carrying the respectively
germlinemutations. Interestingly, none of these patients had germline
mutations in cKIT or PDGFRA genes, which were frequently mutated in
the sporadic and familial GISTs [76,112].
In contrast with the Carney–Stratakis syndrome, in the Carney
triad (CT), which describes the association of paragangliomas with
gastrointestinal stromal tumors and pulmonary chondromas, none of
the affected patients have been found to possess mutations in the
genes encoding the subunits A, B, C or D of SDH or in the cKIT or
PDGFRA genes. Although the tumors related to this syndrome show a
similar pattern of genetic changes, the genetic defects associated with
this condition are still elusive [113].
Recently, inactivatinggermlinemutations in SDHBor SDHCwere also
identiﬁed in sporadic GISTs occurring in patients without a personal or
family history of paraganglioma. These tumors lacked cKIT or PDGFRA
mutations [114].
Renal tumors, which have been described in association or not with
paraganglial tumors, have also been described in patientswith germline
SDHB mutations. Recently, Ricketts and co-authors have reported
that the risk of developing renal tumors in SDHB mutation carriers is
14% at the age of 70 years [35]. These tumors, which generally occur at
young age, present various histological subtypes, including clear cell
renal carcinoma [23,35,89,90,115], eosinophilic chromophobe renal
cell carcinoma, [90], oncocytoma [116] and malignant type II papillary
renal cell carcinoma [88]. Moreover, three different cases of renal
angiomiolipoma [93], renal oncocytoma [94] and hybrid renal cell
carcinoma chromophobe/oncocytoma tumor have been observed in
carriers of large SDHB deletions. In the latter cases the causative role
of the SDHB large deletion was suggested by loss of heterozygosity at
the SDHB locus within the tumors [97]. Recently a case of renal cancer
has been also described in a SDHDmutation carrier [35].
In addition both papillary and medullary thyroid carcinoma have
also been associated with SDHB and SDHD mutations [23,35,91].
A unique case of testicular seminoma has been reported in a carrier
of germline SDHD mutations, which showed loss of the wild type
allele in tumor cells [117].
The common neural crest embryonal origin of both phaeochro-
mocytoma and neuroblastoma (NBL) and the frequent loss of the
locus 1p35-36 in the latter tumors, a region where SDHB gene resides,
suggested that genetic alterations in SDHBmight be implicated in the
development or progression neuroblastoma tumors. Previous studies
have provided no association between SDHB point mutations and
sporadic neuroblastomas [118,119]. However, recently, two different
cases of patients affected by neuroblastomas have been both associated
to germline SDHB deletions. The ﬁrst case reported was of a patient
affected by a familial phaeochromocytoma, who was diagnosed with a
malignant adrenal neuroblastoma at the age of 5 years. Both phaeo-
chromocytomas and the neuroblastoma from this patient with SDHB
deletion showed 1p36 loss, suggesting a possible correlation between
SDHB mutation and neuroblastoma susceptibility [94]. The second
case described a composite paraganglioma/neuroblastoma in a 13 years
old patient, who had no family history of familial PGL tumors [87].
Recently, a further case of malignant neuroblastoma, was identiﬁed
in a index case of a PGL susceptible family, carrying a SDHB mutation.
This patient synchronously developed a malignant neuroblastoma,
phaeochromocytoma and renal cell carcinoma [115].
4. Mechanism of tumorigenesis caused by SDH mutations
Although a role of mitochondria in tumorigenesis has been
suggested by the identiﬁcation of many somatic mutations in the
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of these mutations to tumor initiation or progression is unclear.
The discovery that germline mutations in nuclear genes encoding
SDH subunits lead to development of HPGL/PCC cancer syndrome,
represented the ﬁrst unequivocal link between a genetic mitochon-
drial defect and tumor development.
To explain how loss-of-function mutations of SDH lead to tumor
formation, two leading biochemical mechanisms have been proposed.
These are represented by the metabolic signaling role of succinate,
as an intracellular messenger between mitochondria to cytosol and
by redox stress resulting from increased reactive oxygen species
(ROS) production in mitochondria (Fig. 2). These mechanisms may
be not mutually exclusive.
The ﬁrst model implies that, due to SDH dysfunction, accumulated
succinate leaves the mitochondria via the dicarboxylate carrier and
inhibits the activity of enzymes such as HIFα prolyl hydroxylases
(PHDs) in the cytosol, leading to the induction of a hypoxic response
under normoxic conditions (pseudo-hypoxia) (Fig. 2) [120]. This
response is mediated by the oxygen regulated HIF transcription factor,
the physiological function of which is to promote adaptation of cellsFig. 2. Mechanisms of tumorigenesis due to SDH inactivation. Different mechanisms have
function of SDH could cause accumulation of succinate and the production of reactive oxygen
to the induction of hypoxic response under normoxic conditions (pseudo-hypoxia). In a
dioxygenases or PHD3-mediated developmental apoptosis of neuronal cells or it could lead
instead result in oxidative damage to DNA and genomic instability.to low oxygen tension (hypoxia) [121]. In normoxic conditions, HIFα
is labile due to proteasomal degradation, following the oxygen-
dependent ubiquitination by an ubiquitin ligase complex targeted to
HIFα by the von Hippel-Lindau (VHL) protein. VHL recognition of HIF
requires hydroxylation of two proline residues on HIFα by the PHD
enzymes, which use oxygen and α-ketoglutarate as substrate, and
iron and ascorbate as co-factors [121]. Thus, in normoxic conditions,
HIFα after the modiﬁcation given by PHD enzymes, can be bound
by VHL protein, polyubiquitylated and degradated. However, if PHDs
are inhibited by the accumulated succinate, HIFα is not hydroxylated
and can escape degradation. HIFα then migrates from the cytosol
into the nucleus, where it can heterodimerize with HIFβ to forms an
active complex that induces the expression of genes involved in
angiogenesis, proliferation, cell survival and glycolysis [121].
In support to this model Gimenez-Roqueplo and co-authors
studied the biological effect of SDHD and SDHB mutations in tumors
from PGL families, showing a complete loss of complex II functions in
the respiratory chain of these tumor tissues, with an activation of the
HIF pathway and the consequent angiogenic response, in agreement
with the high vascularization of these types of tumor [15,16]. Pollardbeen proposed to explain the link between SDH mutations and tumorigenesis. Loss of
species (ROS). Both succinate and ROS could independently or in a sinergetic way, lead
ddition to pseudohypoxia, succinate might inhibit other α-ketoglutarate-dependent
to dysregulation of the G-protein-coupled receptor (GPCRs). ROS accumulation might
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SDH-deﬁcient paragangliomas accumulated succinate and displayed
increased expression of HIF1α and VEGF, with high density of
microvessels [122]. Interestingly, tumors deﬁcient for the FH enzyme,
which catalyzes the subsequent step in the Krebs cycle after SDH, also
displayed high vascularity, increased HIFα levels and activity and
accumulation of both succinate and fumarate [122,123]. High levels of
succinate and HIF1α accumulation and nuclear translocation were
demonstrated in SDHA-deﬁcient cells by Briere and co-authors [110].
Moreover, a gene expression micro-arrays analysis of 76 sporadic and
hereditary phaeochromocytomas conﬁrmed a hypoxic-angiogenic
gene expression proﬁle that was similar in tumors from patients
carrying SDHB, SDHD or VHL mutations [124]. A hypoxic transcrip-
tional signature, that was common between SDH and VHL tumors was
also described subsequently in a recent study performed by Lόpez-
Jiménez and colleagues: both HIF1α and HIF2α target genes were
found over-expressed in the SDH/VHL cluster, suggesting that a
global HIF deregulation describes the common proﬁle these tumors.
Despite this common transcriptional proﬁle, a high number of HIF
target genes were also found differentially expressed between SDHB
and VHL cluster, suggesting that speciﬁc HIF target genes could
inﬂuence the different clinical features between these two types of
tumor (extra-adrenal PGLs usually malignant in the SDHB-associated
cases and adrenal PCCs typically benign in the VHL-associated cases)
[125]. Another study also showed an analogous angiogenic proﬁle in
SDH and VHL tumors and although both specimens demonstrated
a decrease in electron transport protein expression and activity, the
stimulation of glycolysis was only found in VHL tumors [126].
The biochemical explanation for the pseudohypoxic drive induced
by loss of function of SDH enzyme was reported by Selak and co-
authors [120]. This work showed that succinate caused HIF stabiliza-
tion, by interfering with the PHD2 (also known as HPH-2 or EglN1)
activity. In fact PHD enzymes, catalyzing HIF-α prolyl hydroxylation,
couple decarboxylation of α-ketoglutarate to succinate. Therefore the
authors demonstrated that SDH downregulation in vitro increased
levels of succinate, which by feedback inhibition of HIF-α PDH in
the cytosol, led to a stabilization of HIF1α transcription factor in
normoxic conditions. As a consequence HIF target genes, which lead
to angiogenesis, glycolysis andmetastasis, were activated [120]. It was
subsequently shown that fumaratewhich accumulates in FH-deﬁcient
cells and tumors, was able to inhibit PHD activity, more effectively
than succinate, and so to cause HIF accumulation and activation [127].
Besides metabolic signaling given by accumulated succinate and
fumarate, other mitochondrial messenger molecules, which have
been suggested to participate in tumorigenesis due to loss of function
of SDH enzyme, are represented by reactive oxygen species (ROS).
Important sites for ROS production in the electron transport chain
are complex I (NADH-ubiquinone oxidoreductase) and complex III
(ubiquinone-cytochrome c oxidoreductase) [128]. Complex II is not
normally considered as amajor site of ROS, but increasing experimental
evidence has demonstrated that SDH mutations lead to oxidative
stress, reduced lifespan in model organisms, genomic instability and
tumorigenesis.
Structural and functional analysis of bacterial SDH suggested
a mechanism for ROS production during the electron transport at the
complex II, exactly at the FAD sites of the subunit A of SDH [129].
The ﬁrst experimental evidence for a feasible ROS production by SDH,
came from the study ofmev-1mutant of Caenorhabditis elegans, which
carried a homozygous inactivation mutation in the SdhC subunit.
This mutation did not affect the SDH's ability to oxidize succinate to
fumarate in the Krebs cycle, but compromised its ability to catalyze
the electron transport from succinate to the ﬁnal acceptor ubiquinone,
leading to electrons leakage. Consequently this mutant was found to
develop oxygen hypersensitivity and a premature aging phenotype
[130]. The equivalent SDHC genemutation studied in C. elegansmev-1,
was then expressed in NIH3T3 mouse ﬁbroblasts. In accordance withthe worm model, transgenic SDHC mutant cells exhibited elevated
oxidative stress, DNA hypermutation, an increased rate of transfor-
mation and tumor growth in amouse xenograftmodel [131]. A further
study, where a nonsense mutation of SDHCwas expressed in hamster
ﬁbroblasts, evidenced increased levels of ROS production, oxidative
stress and genomic instability of the mutant cells compared to the
parental ones [132]. In addition, functional studies in the yeast model
of sdha or sdhb gene deletion [133] and of sdhb [134], sdhc and sdhd
point mutations [135], were associated to an increased production of
ROS, showing that the dysfunction of all the SDH subunits in the yeast
lead to the formation of reactive oxygen species. However, inhibition
either pharmacologically or via RNA interference of SDHB or SDHA
subunits in human cells showed that, while SDHB inhibition increases
normoxic reactive oxygen species production and HIFα accumulation,
complex II inhibition at SDHA does not increase normoxic ROS
levels and HIFα [136]. Conversely, other studies reported no signs of
ROS production and oxidative stress owing to SDH mutations, but
HIF1α accumulation and activation, which depend on succinate-
mediated PHD inhibition, as demonstrated in cells in which SDHD
was downmodulated by means of RNA interference [120,137] or in
SDHA-mutant ﬁbroblasts [110]. In addition, it has been reported that
the SDHB gene knock-down by RNA interference in human cells did
not result in ROS production and the further expression of SDHB
missense mutants in SDHB silenced cells did not affect ROS levels.
However, SDHB inactivation resulted in an up-regulation of HIF1α and
HIF2α and in a defective cellular proliferation and respiration with
a corresponding shift to glycolysis [138]. Whether the contrasting
observations regarding the ROS production consequent to SDHB, SDHD
and especially to SDHA genes inactivation, are due to biological or
technical reasons is to be determined.
In addition of mutagenesis, it has been proposed that reactive
oxygen species might promote tumor formation in SDH-deﬁcient cells
by inducing apseudo-hypoxic response. It has been reported in fact, that
reactive oxygen species can inhibit HIF PHD activity under normoxic
conditions, by promoting the oxidation of the PHDcofactors ferrous iron
and ascorbate [139]. Conversely, in support of a predominant role of
succinate and fumarate in inducing pseudohypoxia through the
inhibition of PHD enzymes, it has been demonstrated that succinate-
and fumarate-mediated PHD inhibition could be reversed by increasing
the intracellular levels of α-ketoglutarate. MacKenzie and co-authors
demonstrated in fact, that cell-permeable esters of α-ketoglutarate
restored normal PHDactivity and thus alleviated pseudohypoxia caused
by the accumulation of these metabolites [140]. Briere and co-authors
demonstrated that exogenous α-ketoglutarate prevented the nuclear
translocation of HIF in SDHA-mutant cells [110].
Beyond to pseudohypoxia and ROS models, it has also been
proposed that SDH mutations cause phaechromocytoma because,
during embryogenesis, neuronal precursor cells which carry muta-
tions in SDH fail to undergo apoptosis in response to growth factor
withdrawal. This developmental apoptosis, which is c-Jun dependent,
is mediated by prolyl hydroxylase PHD3 (also known as EglN3 or
HPH-1), the activity of which is inhibited, as demonstrated for PHD2,
by succinate accumulation [141]. This model was further supported
by a recent study of PDH3 knock-out mice, which showed reduced
apoptosis of sympathetic neurons [142].
Another appealing possibility is that accumulated succinate in
SDH-deﬁcient tumors might inhibit other components of the α-
ketoglutarate-dependent dioxygenase family, besides the prolyl
hydroxylases PHD2 and PHD3. This family comprises numerous
enzymes involved in a wide range of biological roles, such as collagen
biosynthesis, hypoxic signaling, fatty acid metabolism, histone and
nucleic acid demethylation, hydroxylation of proteins associated with
RNA splicing, carnitine metabolism and hydroxylation of 5-methyl-
cytosine [143].
Someof theα-ketoglutarate-dependent enzymesmight have a role
in cell transformation, leading to different biochemical outcome that
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inhibited dioxygenases, might have a tissue speciﬁc expression, which
might contribute to the speciﬁc tumors spectrum of the inherited
neoplasia syndromes given by SDHmutations.
Recently, the ﬁrst evidence supporting this hypothesis was
reported. It has been demonstrated that loss of Sdhb subunit in a
yeast model led to succinate accumulation, which could cause the
inhibition of two different α-ketoglutarate-dependent dioxygenases
[133]. The ﬁrst enzyme was Jlp1, involved in sulfur metabolism, while
the second one was represented by the histone demethylases Jhd1,
which belongs to the JmjC-domain-containing histone demethylases
(JHDMs) enzymes class. Moreover, the authors showed that also the
mammalian JmjC-domain histone demethylases were susceptible to
succinate inhibition. They demonstrated that JMJD2D, a corresponding
human JHDMs, as a puriﬁed enzyme orwhen expressed inmammalian
cells, was inhibited by succinate. Therefore, it has been suggested
that succinate accumulation by inhibiting the histone demethylases,
might alter the expression of oncogenes and tumor suppressor genes,
such as those responsible for DNA repair, growth inhibition or induction
of apoptosis, thus leading to a possible transformed phenotype [133].
Because of their histone demethylase activity, JHDMsenzymes probably
have a wide impact on gene expression, though they may regulate
particular genes by speciﬁc recruitment of interacting proteins, thus
deﬁning an epigenetic signature which might be speciﬁc for the tumor
spectrum of PGL inherited neoplasias.
Recent evidence corroborates the notion of a possible role for
succinate in epigenetic dysregulation of chromatin remodeling,
through the inhibition of histone demethylase JHDMs enzymes. It
has been reported that SDH inactivation, either pharmacological and
by RNA interference, led to an increased methylation of histone H3 in
mammalian cells, which can be reversed by the over expression of the
JMJD3 histone demethylase. This increased histone methylation in
SDHB-silenced cells determined a decreased occupancy by H3K27me3
of the core promoter regions in the IGFBP7 gene, a tumor related
soluble factor, whose transcript was previously found up-regulated in
a study of microarray analysis in SDHB-silenced cells [138]. Moreover,
type I chief cells, which are considered the neoplastic component of
paragangliomas, were the major immunoreactive cells type for both
H3K27me3 and H3K36me2 in the paraganglial carotid tumors tested
[144]. Interestingly, these ﬁndings demonstrated that succinate could
act not only as a messenger between mitochondria to cytosol, but
also as a signal between mitochondria to nucleus, in order to regulate
chromatin structure and thus gene expression.
Another possibility to explain the role of the SDH mutations in
HPGL/PCC tumorigenesis is represented by a non-physiological role
of succinate through its cognate receptor GPR91. It is known that
the intermediates of the citric acid cycle, which are regulated
by respiration, metabolism and renal reabsorption/extrusion, are
normally present in mitochondria, and are also found at micromolar
concentrations in blood. It was shown in 2004 that the citric acid cycle
intermediate succinate is the ligand for the G-protein-coupled
receptors (GPCRs) GPR91 (also known as SUCRN1) [145]. Therefore
by acting as ligand for GPR91, succinatewas found to have unexpected
signaling functions beyond its traditional role as a Krebs cycle
metabolite. This suggests that accumulated succinate, dysregulating
the physiological activity of the G-protein-coupled GP R91 receptor,
could lead to sustained signaling pathway, which might play a role in
the HPGL/PCC tumorigenesis. Interestingly, recent studies of gene
expression by microarray analysis revealed that GPR91 was signiﬁ-
cantly up-regulated in SDHB-silenced cells. Moreover, GPR91 mRNA
was induced also in VHL negative cells and in HepG2 cells after
overexpression of HIF2α [138]. All these ﬁndings suggest that
GPR91 might be a HIF transcriptional target gene. Furthermore,
in ischemic retina succinate, acting through GPR91, was found to
mediate vessel growth through the release of proangiogenic factors
vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1)and Ang-2 by the retinal ganglion neurons, in a HIF1α-independent
manner [146]. This suggests that in SDH-associated tumors succinate
could stimulate by a paracrine signaling, the proliferation of
endothelial cells. These pro-angiogenic effects can synergize with
the possible vascularization mediated by HIF signaling during
pseudohypoxia. Thus, beyond the traditional role in energy produc-
tion, succinate might exhibit through the activation of its receptor
GPR91, additional biological functions, that when altered might
promote tumor onset and progression.
5. Conclusions
SDHwas the ﬁrst nuclear-encoded mitochondrial tumor suppressor
gene to be identiﬁed.
Despite the rapid and important progress achieved since the
discovery of the ﬁrst SDHD gene mutation a decade ago, many
fundamental questions regarding the role of SDH in tumorigenesis
remain to be answered. Mutations in each of the components of
complex II have been shown to disturb complex formation and
subsequently decrease the enzymatic activity of the remaining complex.
Although the mechanism linking SDH deﬁciency to tumorigenesis
remains poorly understood, compelling evidence showed that SDH
inactivation leads to pseudohypoxia.
However it remains to be determined if succinate alone, or ROS,
or combination of both are required to induce pseudohypoxia in
SDH-deﬁcient tumors. In addition, pseudo-hypoxia could not explain
the different and restricted patterns of tumor predisposition that
develop in HPGL/PCC tumorigenesis compared to HLRCC tumorigen-
esis, caused by mutations in FH gene. Pseudohypoxia alone is
probably insufﬁcient to induce HPGL/PCC tumors and it is feasible
that the tumorigenic effect of SDH deﬁciency involves more than one
mechanism.
The possibility that succinate could inhibit other α-ketoglutarate-
dependent enzymes, is appealing. A recent study has indicated
that the human genome encodes more than 60 known or predicted
α-ketoglutarate-dependent dioxygenases [143]. Many of these,
such as the Jumonji-domain histone demethylases, have credible
roles in oncogenesis, and dysregulation might contribute to tumor
predisposition [147,148]. Interestingly, a genomewide screening of
renal cancer has identiﬁed mutation in histones modiﬁcation
enzymes [149]. Moreover, it has been reported that succinate and
fumarate have different IC50 (half maximal inhibitory concentration)
values for α-ketoglutarate-dependent enzymes [150], which might
contribute to explain the speciﬁc tumors spectrum associated to
SDH or FH mutations. However, it remains still unclear which α-
ketoglutarate-dependent enzymes are effectively the relevant targets
for succinate inhibition in the etiology of familial PGLs.
Further basic and therapeutic research is needed to answer these
questions, which could be crucial for the discovery of new therapeutic
targets capable of counteracting SDH-associated tumorigenesis.
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